Analysts Set MaxCyte, Inc. (NASDAQ:MXCT) Target Price at $7.00

MaxCyte, Inc. (NASDAQ:MXCT) has been assigned a consensus rating of “Hold” from the five analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $7.00.

MXCT has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Wall Street Zen cut MaxCyte from a “hold” rating to a “sell” rating in a report on Saturday.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Prudential Financial Inc. acquired a new stake in shares of MaxCyte in the second quarter worth approximately $26,000. CWM LLC increased its position in MaxCyte by 92.7% during the second quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after purchasing an additional 5,836 shares during the last quarter. State of Wyoming purchased a new position in MaxCyte during the second quarter worth approximately $38,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of MaxCyte during the 2nd quarter worth $40,000. Finally, Kwmg LLC raised its position in shares of MaxCyte by 75.8% in the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after buying an additional 11,135 shares during the period. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Price Performance

NASDAQ:MXCT opened at $0.78 on Monday. The firm has a market cap of $83.20 million, a PE ratio of -1.77 and a beta of 1.22. The firm has a 50 day simple moving average of $1.05 and a 200-day simple moving average of $1.38. MaxCyte has a 1-year low of $0.64 and a 1-year high of $3.58.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.